Andrew J. Murphy
2019
In 2019, Andrew J. Murphy earned a total compensation of $9.5M as Executive Vice President, Research at Regeneron Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $666,900 |
|---|---|
| Option Awards | $3,526,669 |
| Salary | $600,000 |
| Stock Awards | $4,702,308 |
| Other | $23,470 |
| Total | $9,519,347 |
Murphy received $4.7M in stock awards, accounting for 49% of the total pay in 2019.
Murphy also received $666.9K in non-equity incentive plan, $3.5M in option awards, $600K in salary and $23.5K in other compensation.
Rankings
In 2019, Andrew J. Murphy's compensation ranked 814th out of 13,971 executives tracked by ExecPay. In other words, Murphy earned more than 94.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 814 out of 13,971 | 94th |
Division Manufacturing | 284 out of 5,701 | 95th |
Major group Chemicals And Allied Products | 79 out of 2,200 | 96th |
Industry group Drugs | 65 out of 1,886 | 97th |
Industry Pharmaceutical Preparations | 53 out of 1,398 | 96th |
Source: SEC filing on April 24, 2020.
Murphy's colleagues
We found four more compensation records of executives who worked with Andrew J. Murphy at Regeneron Pharmaceuticals in 2019.
2019
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer
2019
George Yancopoulos
Regeneron Pharmaceuticals
Chief Scientific Officer
2019
Robert Landry
Regeneron Pharmaceuticals
Chief Financial Officer
2019
Daniel Van Plew
Regeneron Pharmaceuticals
Executive Vice President and General Manager, Industrial Operations and Product Supply
News
Regeneron Pharmaceuticals Executive Vice President and General Manager, Industrial Operations and Product Supply Daniel Van Plew's 2021 pay rises 1% to $8.8M
April 21, 2022
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2020 pay jumps 531% to $135M
April 23, 2021
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2019 pay slips 19% to $21M
April 24, 2020